DK0842944T3 - Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4 - Google Patents

Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4

Info

Publication number
DK0842944T3
DK0842944T3 DK97119639T DK97119639T DK0842944T3 DK 0842944 T3 DK0842944 T3 DK 0842944T3 DK 97119639 T DK97119639 T DK 97119639T DK 97119639 T DK97119639 T DK 97119639T DK 0842944 T3 DK0842944 T3 DK 0842944T3
Authority
DK
Denmark
Prior art keywords
vla
heterocycles
antagonists
inhibitors
leukocyte adhesion
Prior art date
Application number
DK97119639T
Other languages
Danish (da)
English (en)
Inventor
Christoph Huels
Dirk Seiffge
Volkmar Wehner
Hans Ulrich Stilz
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0842944T3 publication Critical patent/DK0842944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97119639T 1996-11-15 1997-11-10 Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4 DK0842944T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19647382A DE19647382A1 (de) 1996-11-15 1996-11-15 Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten

Publications (1)

Publication Number Publication Date
DK0842944T3 true DK0842944T3 (da) 2003-10-27

Family

ID=7811832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97119639T DK0842944T3 (da) 1996-11-15 1997-11-10 Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4

Country Status (28)

Country Link
US (2) US5998447A (cs)
EP (1) EP0842944B1 (cs)
JP (1) JP4510160B2 (cs)
CN (1) CN1133647C (cs)
AR (1) AR010066A1 (cs)
AT (1) ATE244725T1 (cs)
AU (1) AU736595B2 (cs)
BR (1) BR9705726A (cs)
CA (1) CA2220822A1 (cs)
CZ (1) CZ292521B6 (cs)
DE (2) DE19647382A1 (cs)
DK (1) DK0842944T3 (cs)
ES (1) ES2202533T3 (cs)
HR (1) HRP970606B1 (cs)
HU (1) HUP9702034A3 (cs)
IL (1) IL122186A (cs)
MX (1) MX9708781A (cs)
MY (1) MY118176A (cs)
NO (1) NO317242B1 (cs)
NZ (1) NZ329177A (cs)
PL (2) PL323130A1 (cs)
PT (1) PT842944E (cs)
RU (1) RU2220977C2 (cs)
SI (1) SI0842944T1 (cs)
SK (1) SK284349B6 (cs)
TR (1) TR199701356A2 (cs)
TW (1) TW580501B (cs)
ZA (1) ZA9710245B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
IL142816A0 (en) 1998-12-24 2002-03-10 Du Pont Pharm Co SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
DE19922462A1 (de) * 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6503901B1 (en) 1999-10-08 2003-01-07 Bristol Myers Squibb Pharma Company Amino lactam sulfonamides as inhibitors of Aβ protein production
PL357109A1 (en) 1999-12-28 2004-07-12 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001055121A1 (en) * 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
CA2395862A1 (en) 2000-02-17 2001-08-23 Hong Liu Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
WO2001074784A1 (en) 2000-04-03 2001-10-11 Dupont Pharmaceuticals Company CYCLIC LACTAMS AS INHIBITORS OF A-β PROTEIN PRODUCTION
EP1268433A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta-protein production
JP2004500419A (ja) 2000-04-11 2004-01-08 デュポン　ファーマシューティカルズ　カンパニー Ａβタンパク質産生阻害剤としての置換ラクタム
CA2379445C (en) 2000-06-01 2007-08-21 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10111877A1 (de) * 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
US7630761B2 (en) * 2005-11-04 2009-12-08 Cardiac Pacemakers, Inc. Method and apparatus for modifying tissue to improve electrical stimulation efficacy
BRPI0708042A2 (pt) * 2006-06-20 2011-05-17 Isu Abxis Co Ltd método de prevenção ligação de células imunes a outras células, "decoy" de bst2, constructo quimérico, anticorpo monoclonal, método para isolar um ligante para bst2, camundongo transgênico cujas células do somatoplasma e células germinativas compreendem um gene bst2 ou damp funcionalmente prejudicado, camundongo transgênico cujas células do somatoplasma e células germinativas compreendem um gene damp que é totalmente ou parcialmente substituìdo por um gene bst2, método para redução de inflamação em um paciente, método para tratamento de um paciente quanto a sintomas de uma doença associada com inflamação, e método de teste para determinação de um composto quìmico eficaz para inibir ligação célula-célula mediada por bst2
RU2322440C1 (ru) * 2006-09-21 2008-04-20 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) Замещенные омега-азолилалкананилиды, способ их получения и применение в качестве антиагрегантов
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8759384B2 (en) 2008-05-12 2014-06-24 David J. Bearss Oxo-imidazolyl compounds
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
CA2816016A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL136473C (cs) * 1968-02-19
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
JPH07504222A (ja) * 1992-02-19 1995-05-11 ザ・バイオメンブレイン・インスティテュート 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
WO1994015958A2 (en) * 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
CA2193828A1 (en) * 1994-06-29 1996-01-11 Timothy P. Kogan Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
PT796855E (pt) * 1996-03-20 2002-07-31 Hoechst Ag Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
JP4510160B2 (ja) 2010-07-21
SK284349B6 (sk) 2005-02-04
CN1133647C (zh) 2004-01-07
CZ292521B6 (cs) 2003-10-15
DE19647382A1 (de) 1998-05-20
ES2202533T3 (es) 2004-04-01
PT842944E (pt) 2003-11-28
TR199701356A3 (tr) 1998-06-22
HRP970606B1 (en) 2003-08-31
PL188042B1 (pl) 2004-11-30
TW580501B (en) 2004-03-21
SI0842944T1 (en) 2004-02-29
HRP970606A2 (en) 1998-08-31
DE59710411D1 (de) 2003-08-14
IL122186A0 (en) 1998-04-05
AR010066A1 (es) 2000-05-17
SK152597A3 (en) 1998-06-03
EP0842944A3 (de) 1999-02-24
IL122186A (en) 2003-05-29
US6514952B1 (en) 2003-02-04
US5998447A (en) 1999-12-07
CA2220822A1 (en) 1998-05-15
HUP9702034A3 (en) 1998-12-28
TR199701356A2 (xx) 1998-06-22
HUP9702034A2 (hu) 1998-07-28
JPH10147574A (ja) 1998-06-02
AU4525797A (en) 1998-05-21
PL323130A1 (en) 1998-05-25
BR9705726A (pt) 1999-07-20
ATE244725T1 (de) 2003-07-15
HU9702034D0 (en) 1998-01-28
NZ329177A (en) 1998-11-25
NO975245L (no) 1998-05-18
CZ360097A3 (cs) 1998-06-17
EP0842944B1 (de) 2003-07-09
EP0842944A2 (de) 1998-05-20
MY118176A (en) 2004-09-30
NO317242B1 (no) 2004-09-27
MX9708781A (es) 1998-05-31
AU736595B2 (en) 2001-08-02
CN1193022A (zh) 1998-09-16
ZA9710245B (en) 1998-05-13
RU2220977C2 (ru) 2004-01-10
NO975245D0 (no) 1997-11-14

Similar Documents

Publication Publication Date Title
DK0842944T3 (da) Heterocycler som inhibitorer af leukocytadhæsionen og som antagonister af VLA-4
DK0842945T3 (da) Heterocykliske forbindelser som inhibitorer af leukocytadhæsionen og VLA-4-antagonister
DK0842943T3 (da) 5-Ring-heterocykliske forbindelser som inhibitorer af leukocytadhæsion og som VLA-4-antagonister
DK1049662T3 (da) Inhibitorer af alpha4-medieret celleadhæsion
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
NO20000410D0 (no) Dipeptid og beslektede forbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
DK0923585T3 (da) Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
EE9900006A (et) Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena
EE9900600A (et) Uued amidinoderivaadid ja nende kasutamine trombiini inhibiitoritena
DK1498124T3 (da) Anvendelse af inhibitorer i renin-angiotensinsystemet
DK1047450T3 (da) Kombinationer af ACE-inhibitorer og MMP-inhibitorer
DE59708269D1 (de) Cyclische adhäsionsinhibitoren
DE69720957T2 (de) Ace-hemmer
NO940997D0 (no) Guanidinyl-substituerte heterocykliske trombin-inhibitorer
FI941265A0 (fi) Heterosyklisiä sulfoniamidotrombiini-inhibiittoreiHeterosyklisiä sulfoniamidotrombiini-inhibiittoreita ta
FI943259A0 (fi) Soluadheesion peptidi-inhibiittorit